MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10787-025-02104-2

Медицинская библиотека · Inflammopharmacology · 2026

Narrative review on the development of multi-target pharmacological agents for the management of rheumatoid arthritis.

Dhanush Yarava, Ganesh Vakkalagadda Siva

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting 1–2% of the global population, characterized by systemic inflammation and progressive joint damage. The disease’s complex pathophysiology involves multiple immunological cells, inflammatory cytokines, and non-immune components, limiting the effectiveness of single-target therapeutic approaches.

OBJECTIVE

This review examines the limitations of single-target pathways in RA treatment and explores the advantages of multi-target therapeutic strategies in improving patient outcomes through simultaneous modulation of multiple inflammatory cascades.

METHODS

A comprehensive review of single-target pathways (MAPK, JAK-STAT, PI3K/AKT/mTOR signalling) and multi-target approaches was conducted, including analysis of current pharmacological agents, mechanisms of action, and clinical applications. KEY FINDINGS: Single-target therapies demonstrate significant limitations including incomplete symptom control, compensatory mechanisms, and treatment resistance. Multi-target approaches address these shortcomings through dual cytokine inhibition (TNF-α/IL-17, IL-6/IL-1), JAK inhibitors with broad-spectrum activity, and combined T-cell/B-cell targeting strategies. Current therapeutic options include JAK inhibitors (tofacitinib, baricitinib, upadacitinib), TNF-α inhibitors, IL-6 inhibitors, and various DMARDs, each with distinct mechanisms and safety profiles.

CONCLUSIONS

Multi-target pharmaceutical approaches represent a significant advancement in RA management by addressing disease complexity through simultaneous pathway modulation. Integration with biomarker-driven precision medicine enables personalized treatment strategies. Despite improved outcomes, challenges remain regarding dosage optimization and long-term safety. Further clinical trials are essential to refine these therapeutic strategies and enhance their applicability across diverse patient populations, ultimately transforming RA management and improving quality of life.

Для цитирования: Dhanush Yarava, Ganesh Vakkalagadda Siva. Narrative review on the development of multi-target pharmacological agents for the management of rheumatoid arthritis.. Inflammopharmacology. 2026. DOI: 10.1007/s10787-025-02104-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.